Catapult exits Lumora

The deal saw Lumora's molecular diagnostics technology for the clinical and industrial sectors merge with ERBA's existing business for in-vitro diagnostic testing.

Since investing in the company, Catapult has assisted in progressing Lumora's non-clinical licence programme and also in developing its platform for clinical applications. Furthermore, the VC supported the business though its commercial launch and subsequent clinical licence deals.

More recently, Lumora signed an asset purchase agreement for Roche Diagnostics to acquire its proprietary nucleic acid heat elution purification technology.

Previous funding
Catapult led a £1.5m funding round for Lumora in May 2011, with the VC investing a little more than £1m and Tate & Lyle Ventures providing the balance, according to unquote" data.

Tate & Lyle Ventures first invested an undisclosed amount in Lumora in January 2007.

The company also received £700,000 from Circadia Ventures via Tate & Lyle Ventures, Catapult and Cambridge University in March 2013.

Company
Lumora was set up in 2002. It provides molecular diagnostic products to the clinical and non-clinical markets. The technology can be used for a range of fields including food safety testing and medical diagnostics.

People
Ed Wass, chief investment officer, led the transaction for Catapult. Laurence Tisi is CEO of Lumora.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• UK / Ireland
• Healthcare
• Catapult Venture Managers